Squarepoint Ops LLC Makes New $311,000 Investment in Certara, Inc. (NASDAQ:CERT)

Squarepoint Ops LLC acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT) in the second quarter, Holdings Channel.com reports. The fund acquired 22,468 shares of the company’s stock, valued at approximately $311,000.

Other large investors have also modified their holdings of the company. Blue Trust Inc. acquired a new stake in shares of Certara during the second quarter worth $26,000. Pineridge Advisors LLC acquired a new stake in Certara during the 4th quarter worth about $28,000. Innealta Capital LLC acquired a new stake in Certara during the 2nd quarter worth about $36,000. Intech Investment Management LLC purchased a new stake in Certara during the second quarter valued at about $152,000. Finally, MQS Management LLC acquired a new position in shares of Certara in the second quarter worth about $162,000. 73.96% of the stock is owned by institutional investors.

Certara Price Performance

CERT opened at $11.45 on Friday. The stock has a fifty day moving average price of $11.86 and a 200 day moving average price of $14.64. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 1 year low of $10.35 and a 1 year high of $19.87. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of -22.90, a PEG ratio of 5.40 and a beta of 1.49.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The firm had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. During the same period in the previous year, the firm posted $0.10 EPS. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. Analysts forecast that Certara, Inc. will post 0.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CERT. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Robert W. Baird cut their target price on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. KeyCorp reduced their target price on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Barclays lowered their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Finally, JMP Securities restated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $17.42.

Insiders Place Their Bets

In other news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.